Today, Edesa Biotech, Inc. (Nasdaq:EDSA), a company specializing in host-directed therapeutics for immuno-inflammatory diseases, released financial data for the quarter ending December 31, 2025. The report also included a business update, highlighting their progress in the clinical-stage biopharmaceutical field.